Health News
Sutter Regional Medical Foundation
Back to previous page
Back to health news main page
Test designed to screen resistance to cancer drug
Last Updated: 2010-07-29 11:56:12 -0400 (Reuters Health)
HONG KONG (Reuters) - Researchers in Japan have designed a test to identify patients who are likely to be resistant to imatinib, the standard drug for treating leukemia, a cancer of the blood cells.
Such a test is important as imatinib resistance usually occurs in relapsed patients, who tend to deteriorate very rapidly if they are given the wrong treatment.
In a paper published in Clinical Cancer Research on Thursday, the scientists said they developed a test that will help doctors tell if a patient with chronic myeloid leukemia (CML) is resistant to imatinib.
Imatinib, known by the brand Gleevec, is used to treat CML and other cancers. It blocks the enzymes of cancer cells instead of killing all rapidly multiplying cells.
"Most patients are sensitive to imatinib when they are diagnosed with CML, but resistance can indeed be acquired during or after imatinib treatment," said Yusuke Ohba, an associate professor at Hokkaido University Graduate School of Medicine.
"Even in cases where resistance develops or becomes apparent gradually, the most critical issue is what to switch over to. If the patient is switched to another (treatment) to which he/she is also resistant, the treatment will just be a waste of time and detrimental to the patient's condition."
"With our test, we can identify the most suitable drug, dose and/or drug combination, enabling therapy to be tailor-made for each individual patient. I believe this approach will make CML care more accurate and effective," he noted in an email to Reuters.
New drugs being developed for treating CML claim to overcome imatinib resistance, but until now, it has been difficult to tell who has that resistance.
Using this test developed by Ohba and his colleagues, blood samples are collected from patients and then cultured and tested to see if they are resistant to imatinib.
These tests should help doctors determine if the patient may require stronger doses, combination therapy, or other drugs, Ohba said.
Clinical Cancer Research, August 2010.
Back to previous page
Back to health news main page
Copyright © 2001-2010 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.